Clinical value of the gene chip technology in detecting the drug resistance of Mycobacterium tuberculosis

Objective To study the clinical value of the gene chip technology in detecting the drug resistance of Mycobacterium tuberculosis. Methods The clinical data of 685 cases with tuberculosis clinical suspected were retrospec tively analyzed and the jingxin biochip technology of Mycobacterium tuberculosis was performed for the detection. Results In the 685 clinical suspected cases,135 cases showed positive results,the positive rate was 19.7%,the detecting result of gene chip technology showed that 131 cases were tuberculosis and 4 cases were non-tuberculosis. and the positive rate was 19.1%,. The resistance gene detection was performed in 68 cases,and there were 12 cases of gene mutations of rifampicin or isoniazid and the overall mutation rate was 17.6%,among them,11 cases were drug resistance of both rifampicin and isoniazid and the double mutation rate was 16.2% and 1 case was only drug resistance of rifampicin.The total mutation rate of rifampin was 17.6%,while the total mutation rate of isoniazid was 16.2%,and the multi-drug resistance rate was 16.2%. Conclusion The jingxin biochip technology of Mycobacterium tuberculosis used for clinical diagnosis of tuberculosis and detecting the drug resistance can shorten the diagnostic time and improve clinical timeliness,which is worthy of popularization and application.